Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2023 ALL Highlights
30 January 2024 | Virtual Meeting
Expert-led presentations & discussions on key abstracts in acute lymphoblastic leukemia (ALL) from ASH 2023
Session 1: CAR-T & bispecifics
CIBMTR: Real-world outcomes of brexu-cel for R/R B-ALL
Evandro Bezerra Ohio State University, Columbus, OH, United States
ROCCA: Brexu-cel in adults with R/R B-ALL
Gregory Roloff UChicago Medicine, Chicago, IL, United States
FELIX: Obe-cel, (AUTO1) for R/R adult B-ALL
Claire Roddie University College London, London, United Kingdom
GIMEMA LAL2317: chemo and blina to improve MRD in adult Ph- B-ALL
Sabina Chiaretti Sapienza University of Rome, Rome, Italy
GMALL BOLD: Dose-reduced chemo with blina for newly diagnosed older pts
Nicola Gökbuget University Hospital Frankfurt, Frankfurt, Germany
Panel discussion: CAR-T & bispecifics
Session 2: Transplant & TKIs
Secondary Malignancies after TBI for HSCT in children with ALL
Anita Lawitschka Saint Anna Children's Hospital, Vienna, Austria
Infusion of UM171-expanded cord blood for HR leukemias
Filippo Milano Fred Hutchinson Cancer Center, Seattle, WA, United States
Asciminib with dasatinib & prednisone for BCR-ABL1+ ALL & blast phase CML
Marlise Luskin Dana-Farber Cancer Institute, Boston, MA, United States
Panel discussion: transplant & TKIs
Session 3: T-ALL
GRAALL-2014/T: frontline consolidation with nelarabine for HR T-ALL
Nicolas Boissel Saint-Louis Hospital, Paris, France
NEL, PEG, and VEN with HCVAD chemo for T-ALL/T-LBL
Jayastu Senapati MD Anderson Cancer Center, Houston, TX, United States
NGS-based stratification identifies very high-risk patients in T-ALL
Mathieu Simonin Hospital Armand Trousseau Ap-Hp, Paris, France
WU-CART-007 in R/R T-ALL/LBL
Armin Ghobadi Washington University School of Medicine in St. Louis, St. Louis, MO, United States
Panel discussion: T-ALL
